Imperative Care Reacquires Truvic, Raises $260m To Advance Neurovascular And Peripheral Interventions
Executive Summary
The proceeds from the series D financing will help Imperative Care advance its stroke-intervention technologies and Truvic’s peripheral intervention devices.
You may also be interested in...
News We’re Watching: Sterigenics Settlement, FDA’s AI Device List Grows, Edwards CE Mark
This week, Sterigenics paid $35m to resolve 79 personal injury claims related to a Georgia facility; recalls were announced for two ventilator lines; and a study found that Zoom aspiration catheters are a lower-cost way to treat some strokes.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.
New’s We’re Watching: J&J's Varipulse PFA Earns CE Mark; Labs Create Intravascular Robots; And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, Biosense Webster’s Varipulse PFA platform earned a CE mark; Biosense Webster also announced the start the pivotal IDE study of its Laminar left atrial appendage elimination system; the FDA approved Boston Scientific's Agent paclitaxel-coated balloon and cleared Medtronic's OsteoCool 2.0 bone ablation system; three papers in Science Robotics describe magnetically controlled vascular robots that could go places wires and catheters cannot.